Delivering a gentle electrical current to the brain, the Fisher Wallace Stimulator stimulates neurotransmitters responsible for healthy sleep and pain suppression.

Health Canada’s approval of the Fisher Wallace Stimulator is based on assessing of safety and effectiveness data obtained from multiple published studies involving hundreds of patients.

Overall, published research and clinical practice indicate that the Fisher Wallace Stimulator has a 75% success rate in reducing or eliminating multiple forms of insomnia and chronic pain.

In these studies, the device has not shown any adverse events and caused no serious side effects.

The portable, battery-powered device is available without a prescription in Canada. Patients can return the device for a refund within 60 days of receipt if it does not relieve their symptoms.

Fisher Wallace Laboratories president Charles Fisher said that Health Canada approval of the Fisher Wallace Stimulator medical device is a significant milestone for the company and for insomnia and chronic pain patients across Canada.

"It means that for many insomnia and chronic pain sufferers, relief is just 20-minutes away," Fisher added.

Fisher Wallace Stimulator obtained approval from the US Food and Drug Administration in 1991 for the treatment of insomnia, anxiety, depression and chronic pain.